The question
Where should a technology-led strategic entrant participate in MedTech, and when is acquisition a more attractive route than building the business organically?
My role
I led the market-entry and screening workstream, evaluating priority MedTech categories and translating the most attractive opportunity spaces into potential inorganic-entry options and acquisition targets.
What mattered
The work focused on five questions:
-
Which MedTech categories offered sufficient market attractiveness and structural growth?
-
How intense was competition, and where were attractive positions already occupied by established players?
-
What technology, regulatory, commercial and channel capabilities were required to compete effectively?
-
Where did the entrant possess a credible right to win through existing capabilities, customer relationships or technology?
-
For priority categories, was organic entry realistic, or could acquisition accelerate access to products, capabilities, channels or market position?
The category screen therefore went beyond market size and growth. Priority opportunities were assessed against competitive intensity, technology requirements, route-to-market dynamics, strategic fit and the feasibility of building versus acquiring the capabilities needed to compete.
The priority spaces were then translated into a target-screening exercise to identify businesses that could potentially provide a faster or stronger route into the selected markets.
The broader lesson
An attractive market does not automatically make an attractive market-entry opportunity.
The more important question is whether the entrant has a credible route to advantage — through technology, capabilities, channel access, customer relationships, acquisition or ecosystem position.
Entry-mode choice should therefore follow strategic advantage, not simply market growth. In some categories, building organically may preserve control and economics; in others, acquisition can materially accelerate the capabilities and access required to compete.